Gilead
EU recommends PrEP in Gilead’s HIV prevention treatment
July 25, 2016Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention
Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …
Gilead receives EU approval for combo hepatitis C treatment
July 11, 2016Sales and Marketing Epclusa, Gilead, eu approval, sofosbuvir
Gilead Sciences (NASDAQ: GILD) has received a marketing authorisation approval from the European Commission for combination treatment Epclusa (sofosbuvir/velpatasvir) for …
Gilead says US FDA approves Epclusa to treat hepatitis C
June 29, 2016Research and Development, Sales and Marketing Epclusa, Gilead, HCV, US FDA, drug approval, regulation
US drug firm Gilead Sciences (Nasdaq: GILD) said the US Food and Drug Administration has approved its Epclusa (sofosbuvir/velpatasvir), in …
Judge reverses verdict in MSD/Gilead hepatitis C dispute
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi
A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …
Gilead names Kevin Young new chief operating officer
May 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead
Gilead Sciences (NASDAQ: GILD) has announced two new senior appointments, including Kevin Young as its new chief operating officer. Martin …
Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies
April 20, 2016Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir
Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …
Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials
April 14, 2016Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier
US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …
IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition
April 11, 2016Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV
German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally …
FDA approves Gilead’s latest HIV treatment
April 5, 2016Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy
Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …
Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute
March 23, 2016Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi
Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …
Revealed: analysts predict seven highest-earning pharma blockbusters
February 4, 2016Sales and Marketing Gilead, OCA, Thomson Reuters, blockbusters, sales
Seven new drugs currently in development will enter the market this year – and earn sales of more than $1 …
Gilead terminates Phase II simtuzumab IPF study
January 6, 2016Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab
Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …
Gilead success in late-stage hepatitis B trials
January 5, 2016Research and Development, Sales and Marketing Gilead, hepatitis B, phase III
Two Phase III trials evaluating Gilead treatments in chronic hepatitis B virus (HBV) infection have met their primary objectives, showing …
Gilead steps in to rescue Galapagos RA drug
December 18, 2015Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis
Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …
Gilead’s Sovaldi wins Drug Discovery of the Year Award
December 16, 2015Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi
Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
